Corcept Therapeutics Incorporated (CORT)
NASDAQ: CORT · IEX Real-Time Price · USD
31.56
-1.11 (-3.40%)
At close: Jul 2, 2024, 4:00 PM
29.44
-2.12 (-6.72%)
After-hours: Jul 2, 2024, 7:44 PM EDT
Corcept Therapeutics Employees
Corcept Therapeutics had 352 employees as of December 31, 2023. The number of employees increased by 53 or 17.73% compared to the previous year.
Employees
352
Change (1Y)
53
Growth (1Y)
17.73%
Revenue / Employee
$1,487,298
Profits / Employee
$332,912
Market Cap
3.29B
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2023 | 352 | 53 | 17.73% |
Dec 31, 2022 | 299 | 61 | 25.63% |
Dec 31, 2021 | 238 | 2 | 0.85% |
Dec 31, 2020 | 236 | 30 | 14.56% |
Dec 31, 2019 | 206 | 40 | 24.10% |
Dec 31, 2018 | 166 | 30 | 22.06% |
Dec 31, 2017 | 136 | 33 | 32.04% |
Dec 31, 2016 | 103 | 7 | 7.29% |
Dec 31, 2015 | 96 | 25 | 35.21% |
Dec 31, 2014 | 71 | 7 | 10.94% |
Dec 31, 2013 | 64 | 8 | 14.29% |
Dec 31, 2012 | 56 | 20 | 55.56% |
Dec 31, 2011 | 36 | 1 | 2.86% |
Dec 31, 2010 | 35 | 8 | 29.63% |
Dec 31, 2009 | 27 | -4 | -12.90% |
Dec 31, 2008 | 31 | 10 | 47.62% |
Dec 31, 2007 | 21 | 1 | 5.00% |
Dec 31, 2006 | 20 | 1 | 5.26% |
Dec 31, 2005 | 19 | -1 | -5.00% |
Dec 31, 2004 | 20 | - | - |
Sources: Annual number of employees according to filings submitted to the U.S. Securities and Exchange Commission (SEC). Data is also manually gathered from company press releases, IPO filings, and other official sources.
Related Stocks
Company Name | Employees |
---|---|
Sotera Health Company | 3,000 |
Neogen | 2,640 |
Oscar Health | 2,400 |
iRhythm Technologies | 2,000 |
Alvotech | 1,026 |
Axonics | 797 |
Prestige Consumer Healthcare | 560 |
Arrowhead Pharmaceuticals | 525 |
CORT News
- 8 days ago - Corcept Announces Presentation of Results From Prevalence Phase of CATALYST Clinical Trial at American Diabetes Association's Scientific Sessions - GlobeNewsWire
- 4 weeks ago - Corcept Therapeutics Announces Presentations of Results of Pivotal Phase 3 GRACE Trial Evaluating Relacorilant in Patients with Hypercortisolism (Cushing's Syndrome) - GlobeNewsWire
- 2 months ago - Levi & Korsinsky, LLP Notifies Shareholders of Corcept Therapeutics Incorporated (CORT) an Upcoming Claims Deadline in a Class Action Settlement - Accesswire
- 2 months ago - Corcept Therapeutics Announces First Quarter Financial Results and Provides Corporate Update - GlobeNewsWire
- 2 months ago - Corcept Therapeutics to Announce First Quarter Financial Results, Provide Corporate Update and Host Conference Call - GlobeNewsWire
- 3 months ago - Corcept Completes Enrollment in Phase 3 Gradient Trial of Relacorilant in Patients With Adrenal Cushing's Syndrome - GlobeNewsWire
- 4 months ago - Corcept Therapeutics Announces Fourth Quarter and Full-Year 2023 Audited Financial Results and Provides Corporate Update - GlobeNewsWire
- 4 months ago - Corcept Announces Preliminary Results From Prevalence Phase Of CATALYST Clinical Trial - GlobeNewsWire